{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T22:20:58Z","timestamp":1788128458841,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015696","name":"Siemens Medical Solutions USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018878","name":"OrbusNeich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022086","name":"Roivant Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs, Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005333","name":"Center for Social Inclusion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015854","name":"Scott R. MacKenzie Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018085","name":"Data Science Institute, Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019361","name":"Belvoir Media Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ahj.2020.09.019","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T22:21:11Z","timestamp":1601936471000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent"],"prefix":"10.1016","volume":"231","author":[{"given":"Marco","family":"Valgimigli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra R.","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hermiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Picon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Toelg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem M.","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan Jenny","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ahj.2020.09.019_bb0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.amjmed.2006.01.023","article-title":"Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials","volume":"119","author":"Bavry","year":"2006","journal-title":"Am J Med"},{"issue":"9562","key":"10.1016\/j.ahj.2020.09.019_bb0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.ahj.2020.09.019_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"Grines","year":"2007","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ahj.2020.09.019_bb0020","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2020.09.019_bb0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.21037\/cdt.2018.10.01","article-title":"The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short","volume":"8","author":"Costa","year":"2018","journal-title":"Cardiovascular diagnosis and therapy"},{"issue":"3","key":"10.1016\/j.ahj.2020.09.019_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ahj.2020.09.019_bb0040","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2020.09.019_bb0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non\u2013ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"Mehran","year":"2009","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ahj.2020.09.019_bb0050","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"Genereux","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2020.09.019_bb0055","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.ahj.2020.09.019_bb0060","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2015.01.047","article-title":"Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention","volume":"65","author":"Kazi","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ahj.2020.09.019_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9852","key":"10.1016\/j.ahj.2020.09.019_bb0070","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","article-title":"Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial","volume":"380","author":"Sabate","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.09.019_bb0075","doi-asserted-by":"crossref","first-page":"g6427","DOI":"10.1136\/bmj.g6427","article-title":"Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis","volume":"349","author":"Valgimigli","year":"2014","journal-title":"BMJ"},{"issue":"10190","key":"10.1016\/j.ahj.2020.09.019_bb0080","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ahj.2020.09.019_bb0085","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"10115","key":"10.1016\/j.ahj.2020.09.019_bb0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ahj.2020.09.019_bb0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17434440.2020.1747434","article-title":"Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy","volume":"17","author":"Mitsis","year":"2020","journal-title":"Expert Rev Med Devices"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","article-title":"Endothelial cell recovery between comparator polymer-based drug-eluting stents","volume":"52","author":"Joner","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ahj.2020.09.019_bb0115","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2020.09.019_bb0120","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jcin.2015.03.029","article-title":"Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model","volume":"8","author":"Otsuka","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.ahj.2020.09.019_bb0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jcin.2013.05.005","volume":"6","author":"Dangas","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"9710","key":"10.1016\/j.ahj.2020.09.019_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","article-title":"Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial","volume":"375","author":"Kedhi","year":"2010","journal-title":"Lancet"},{"issue":"9824","key":"10.1016\/j.ahj.2020.09.019_bb0135","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"issue":"9960","key":"10.1016\/j.ahj.2020.09.019_bb0140","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"issue":"10157","key":"10.1016\/j.ahj.2020.09.019_bb0145","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahj.2020.09.019_bb0150","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.ahj.2020.09.019_bb0155","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahj.2020.09.019_bb0160","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jcin.2011.08.010","article-title":"A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)","volume":"4","author":"Krucoff","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.ahj.2020.09.019_bb0165","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","article-title":"Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study","volume":"5","author":"Naidu","year":"2012","journal-title":"JACC Cardiovasc Interv."},{"key":"10.1016\/j.ahj.2020.09.019_bb0170","first-page":"489","article-title":"Propensity score stratification for observational comparison of repeated binary outcomes","volume":"4","author":"Leon","year":"2011","journal-title":"Statistics And Its Iterface"},{"key":"10.1016\/j.ahj.2020.09.019_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10543400601044691","article-title":"Statistical and regulatory issues with the application of prepensity score analysis to nonrandomized medical device clinical studies","volume":"17","author":"Yue","year":"2007","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.ahj.2020.09.019_bb0180","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2020.09.019_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2018.10.009","article-title":"Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study","volume":"209","author":"Frigoli","year":"2019","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2020.09.019_bb0190","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ahj.2013.01.008","article-title":"Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy","volume":"165","author":"Urban","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.09.019_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2018.08.004","article-title":"Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention","volume":"205","author":"Mauri","year":"2018","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.ahj.2020.09.019_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention","volume":"12","author":"Natsuaki","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.ahj.2020.09.019_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"issue":"21","key":"10.1016\/j.ahj.2020.09.019_bb0215","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320302751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320302751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:40Z","timestamp":1762077460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320302751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":43,"alternative-id":["S0002870320302751"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.09.019","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}